Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial

Mary Gleeson; Eliza A. Hawkes; David Cunningham; Nick Chadwick; Nicholas Counsell; Anthony Lawrie; Andrew Jack; Paul Smith; Paul Mouncey; Christopher Pocock; Kirit M. Ardeshna; John Radford; Andrew McMillan; John Davies; Deborah Turner; Anton Kruger; Peter W.M. Johnson; Joanna Gambell; David Linch

doi:10.1111/bjh.14287

Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial

Mary Gleeson, Eliza A. Hawkes, David Cunningham, Nick Chadwick, Nicholas Counsell, Anthony Lawrie, Andrew Jack, Paul Smith, Paul Mouncey, Christopher Pocock, Kirit M. Ardeshna, John Radford, Andrew McMillan, John Davies, Deborah Turner, Anton Kruger, Peter W.M. Johnson, Joanna Gambell, David Linch

Research output: Contribution to journal › Article › Research › peer-review

42 Citations (Scopus)

Abstract

We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to evaluate the outcomes for 50 patients with World Health Organization 2008 classified primary mediastinal B-cell lymphoma identified from the trial database. At a median follow-up of 7·2 years the 5-year progression-free survival and overall survival was 79·8% and 83·8%, respectively. An exploratory analysis raised the possibility of a better outcome in those who received R-CHOP-14 and time intensification may still, in the rituximab era, merit testing in a randomised trial in this subgroup of patients.

Original language	English
Pages (from-to)	668-672
Number of pages	5
Journal	British Journal of Haematology
Volume	175
Issue number	4
DOIs	https://doi.org/10.1111/bjh.14287
Publication status	Published - Nov 2016
Externally published	Yes

Keywords

clinical trials
diffuse large B-cell lymphoma
non-Hodgkin lymphoma
primary mediastinal B-cell lymphoma
rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bjh.14287

Cite this

Gleeson, M., Hawkes, E. A., Cunningham, D., Chadwick, N., Counsell, N., Lawrie, A., Jack, A., Smith, P., Mouncey, P., Pocock, C., Ardeshna, K. M., Radford, J., McMillan, A., Davies, J., Turner, D., Kruger, A., Johnson, P. W. M., Gambell, J., & Linch, D. (2016). Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. British Journal of Haematology, 175(4), 668-672. https://doi.org/10.1111/bjh.14287

@article{8a7a6b93b2c344119be2827cae3f2a14,

title = "Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial",

abstract = "We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to evaluate the outcomes for 50 patients with World Health Organization 2008 classified primary mediastinal B-cell lymphoma identified from the trial database. At a median follow-up of 7·2 years the 5-year progression-free survival and overall survival was 79·8% and 83·8%, respectively. An exploratory analysis raised the possibility of a better outcome in those who received R-CHOP-14 and time intensification may still, in the rituximab era, merit testing in a randomised trial in this subgroup of patients.",

keywords = "clinical trials, diffuse large B-cell lymphoma, non-Hodgkin lymphoma, primary mediastinal B-cell lymphoma, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone",

author = "Mary Gleeson and Hawkes, {Eliza A.} and David Cunningham and Nick Chadwick and Nicholas Counsell and Anthony Lawrie and Andrew Jack and Paul Smith and Paul Mouncey and Christopher Pocock and Ardeshna, {Kirit M.} and John Radford and Andrew McMillan and John Davies and Deborah Turner and Anton Kruger and Johnson, {Peter W.M.} and Joanna Gambell and David Linch",

year = "2016",

month = nov,

doi = "10.1111/bjh.14287",

language = "English",

volume = "175",

pages = "668--672",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "4",

}

Gleeson, M, Hawkes, EA, Cunningham, D, Chadwick, N, Counsell, N, Lawrie, A, Jack, A, Smith, P, Mouncey, P, Pocock, C, Ardeshna, KM, Radford, J, McMillan, A, Davies, J, Turner, D, Kruger, A, Johnson, PWM, Gambell, J & Linch, D 2016, 'Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial', British Journal of Haematology, vol. 175, no. 4, pp. 668-672. https://doi.org/10.1111/bjh.14287

Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. / Gleeson, Mary; Hawkes, Eliza A.; Cunningham, David et al.
In: British Journal of Haematology, Vol. 175, No. 4, 11.2016, p. 668-672.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma

T2 - a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial

AU - Gleeson, Mary

AU - Hawkes, Eliza A.

AU - Cunningham, David

AU - Chadwick, Nick

AU - Counsell, Nicholas

AU - Lawrie, Anthony

AU - Jack, Andrew

AU - Smith, Paul

AU - Mouncey, Paul

AU - Pocock, Christopher

AU - Ardeshna, Kirit M.

AU - Radford, John

AU - McMillan, Andrew

AU - Davies, John

AU - Turner, Deborah

AU - Kruger, Anton

AU - Johnson, Peter W.M.

AU - Gambell, Joanna

AU - Linch, David

PY - 2016/11

Y1 - 2016/11

N2 - We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to evaluate the outcomes for 50 patients with World Health Organization 2008 classified primary mediastinal B-cell lymphoma identified from the trial database. At a median follow-up of 7·2 years the 5-year progression-free survival and overall survival was 79·8% and 83·8%, respectively. An exploratory analysis raised the possibility of a better outcome in those who received R-CHOP-14 and time intensification may still, in the rituximab era, merit testing in a randomised trial in this subgroup of patients.

AB - We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to evaluate the outcomes for 50 patients with World Health Organization 2008 classified primary mediastinal B-cell lymphoma identified from the trial database. At a median follow-up of 7·2 years the 5-year progression-free survival and overall survival was 79·8% and 83·8%, respectively. An exploratory analysis raised the possibility of a better outcome in those who received R-CHOP-14 and time intensification may still, in the rituximab era, merit testing in a randomised trial in this subgroup of patients.

KW - clinical trials

KW - diffuse large B-cell lymphoma

KW - non-Hodgkin lymphoma

KW - primary mediastinal B-cell lymphoma

KW - rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone

UR - http://www.scopus.com/inward/record.url?scp=84994477294&partnerID=8YFLogxK

U2 - 10.1111/bjh.14287

DO - 10.1111/bjh.14287

M3 - Article

C2 - 27477167

AN - SCOPUS:84994477294

SN - 0007-1048

VL - 175

SP - 668

EP - 672

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 4

ER -

Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this